PE20211785A1 - Mimeticos de calcitonina acilados - Google Patents
Mimeticos de calcitonina aciladosInfo
- Publication number
- PE20211785A1 PE20211785A1 PE2021000229A PE2021000229A PE20211785A1 PE 20211785 A1 PE20211785 A1 PE 20211785A1 PE 2021000229 A PE2021000229 A PE 2021000229A PE 2021000229 A PE2021000229 A PE 2021000229A PE 20211785 A1 PE20211785 A1 PE 20211785A1
- Authority
- PE
- Peru
- Prior art keywords
- calcitonin
- regulation
- treatment
- receptor
- acylated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813678.8A GB201813678D0 (en) | 2018-08-22 | 2018-08-22 | Acylated calcitonin mimetics |
| PCT/EP2019/072533 WO2020039051A1 (en) | 2018-08-22 | 2019-08-22 | Acylated calcitonin mimetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211785A1 true PE20211785A1 (es) | 2021-09-09 |
Family
ID=63668212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000229A PE20211785A1 (es) | 2018-08-22 | 2019-08-22 | Mimeticos de calcitonina acilados |
Country Status (18)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| AR124295A1 (es) | 2020-12-18 | 2023-03-15 | Lilly Co Eli | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| CN118684757A (zh) * | 2023-03-24 | 2024-09-24 | 成都奥达生物科技有限公司 | 一种长效降钙素类似物 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU742270B2 (en) | 1997-04-16 | 2001-12-20 | Enteris Biopharma, Inc. | Direct expression of peptides into culture media |
| JP2002531518A (ja) | 1998-12-04 | 2002-09-24 | プロヴァリス・ユーケー・リミテッド | インスリン含有医薬組成物 |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| EP1608347B1 (en) | 2003-03-28 | 2014-08-13 | Sigmoid Pharma Limited | Solid oral dosage form containing seamless microcapsules |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| JP4829783B2 (ja) * | 2003-06-24 | 2011-12-07 | バイオコン・リミテッド | カルシトニン薬−オリゴマーコンジュゲートの混合物および疼痛治療における使用方法 |
| PT2316473E (pt) | 2003-07-23 | 2013-09-20 | Novartis Ag | Utilização de calcitonina na osteoartrite |
| AU2004317954A1 (en) | 2003-09-17 | 2005-10-13 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
| JP2008506750A (ja) | 2004-07-22 | 2008-03-06 | ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー | チオール基を含む化合物の排出ポンプ抑制剤としての使用 |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| EP1907561B1 (en) | 2005-06-24 | 2013-08-28 | Unigene Laboratories, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| EP2722054B1 (en) | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| PT1834635E (pt) | 2006-03-13 | 2011-10-13 | Advanced In Vitro Cell Technologies S L | Sistemas estáveis de nanocápsula para a administração de moléculas activas |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| EP2405934B1 (en) * | 2009-03-12 | 2014-03-26 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
| WO2011051312A1 (en) * | 2009-10-30 | 2011-05-05 | Novo Nordisk A/S | Derivatives of cgrp |
| JP6231386B2 (ja) * | 2010-11-09 | 2017-11-15 | ノヴォ ノルディスク アー/エス | リンカーを有する二重アシル化されたglp−1誘導体 |
| SI3095484T1 (en) * | 2011-11-02 | 2018-08-31 | Keybioscience Ag | Calcitonin mimetics for the treatment of diseases and disorders |
| US9533022B2 (en) * | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
| CA2854175A1 (en) * | 2011-11-02 | 2013-05-10 | Keybioscience Ag | Peptide analogs for treating diseases and disorders |
| BR112016010643A2 (pt) * | 2013-11-14 | 2017-12-05 | Keybioscience Ag | peptídeo |
| GB201500263D0 (en) * | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
| EP3359181A1 (en) * | 2015-10-07 | 2018-08-15 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide drugs |
| KR102444366B1 (ko) * | 2016-06-03 | 2022-09-19 | 케모센트릭스, 인크. | 간 섬유화 치료 방법 |
-
2018
- 2018-08-22 GB GBGB1813678.8A patent/GB201813678D0/en not_active Ceased
-
2019
- 2019-08-22 EP EP19765419.7A patent/EP3840774A1/en active Pending
- 2019-08-22 CN CN202511289522.2A patent/CN121226531A/zh active Pending
- 2019-08-22 EA EA202190477A patent/EA202190477A1/ru unknown
- 2019-08-22 PE PE2021000229A patent/PE20211785A1/es unknown
- 2019-08-22 CN CN202610554181.5A patent/CN122464982A/zh active Pending
- 2019-08-22 JP JP2021509906A patent/JP2021535119A/ja active Pending
- 2019-08-22 CA CA3110033A patent/CA3110033A1/en active Pending
- 2019-08-22 KR KR1020257032307A patent/KR20250143876A/ko active Pending
- 2019-08-22 CN CN202610554176.4A patent/CN122541545A/zh active Pending
- 2019-08-22 CN CN201980055426.8A patent/CN112601542A/zh active Pending
- 2019-08-22 US US17/270,331 patent/US20220380432A1/en active Pending
- 2019-08-22 BR BR112021003088-3A patent/BR112021003088A2/pt unknown
- 2019-08-22 KR KR1020217008022A patent/KR102866729B1/ko active Active
- 2019-08-22 AU AU2019323697A patent/AU2019323697B2/en active Active
- 2019-08-22 MX MX2021002072A patent/MX2021002072A/es unknown
- 2019-08-22 IL IL280885A patent/IL280885B2/en unknown
- 2019-08-22 WO PCT/EP2019/072533 patent/WO2020039051A1/en not_active Ceased
- 2019-08-22 CN CN202511289422.XA patent/CN121021664A/zh active Pending
-
2021
- 2021-02-09 ZA ZA2021/00869A patent/ZA202100869B/en unknown
- 2021-02-16 PH PH12021550331A patent/PH12021550331A1/en unknown
- 2021-02-19 CL CL2021000427A patent/CL2021000427A1/es unknown
- 2021-02-22 CO CONC2021/0002071A patent/CO2021002071A2/es unknown
-
2024
- 2024-11-05 JP JP2024193478A patent/JP2025023996A/ja active Pending
-
2025
- 2025-07-04 AU AU2025205152A patent/AU2025205152A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021535119A (ja) | 2021-12-16 |
| BR112021003088A2 (pt) | 2021-05-11 |
| CN121226531A (zh) | 2025-12-30 |
| IL280885A (en) | 2021-04-29 |
| US20220380432A1 (en) | 2022-12-01 |
| IL280885B2 (en) | 2024-11-01 |
| CN122464982A (zh) | 2026-07-28 |
| EP3840774A1 (en) | 2021-06-30 |
| JP2025023996A (ja) | 2025-02-19 |
| CO2021002071A2 (es) | 2021-03-08 |
| AU2019323697A1 (en) | 2021-03-04 |
| EA202190477A1 (ru) | 2021-06-04 |
| AU2019323697B2 (en) | 2025-08-07 |
| MX2021002072A (es) | 2021-04-28 |
| KR20210047322A (ko) | 2021-04-29 |
| WO2020039051A1 (en) | 2020-02-27 |
| ZA202100869B (en) | 2022-09-28 |
| CN112601542A (zh) | 2021-04-02 |
| KR102866729B1 (ko) | 2025-10-02 |
| PH12021550331A1 (en) | 2021-10-04 |
| AU2025205152A1 (en) | 2025-07-24 |
| GB201813678D0 (en) | 2018-10-03 |
| CL2021000427A1 (es) | 2021-08-20 |
| CN121021664A (zh) | 2025-11-28 |
| IL280885B1 (en) | 2024-07-01 |
| CN122541545A (zh) | 2026-08-11 |
| CA3110033A1 (en) | 2020-02-27 |
| KR20250143876A (ko) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beals et al. | Obesity alters the muscle protein synthetic response to nutrition and exercise | |
| Hauge et al. | GPR40 (FFAR1)–combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo | |
| Perry et al. | Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas | |
| West et al. | Human exercise-mediated skeletal muscle hypertrophy is an intrinsic process | |
| MX2021002072A (es) | Mimeticos de calcitonina acilados. | |
| PE20220965A1 (es) | Analogos de relaxina y metodos para usarlos | |
| MX2016006049A (es) | Mimeticos de calcitonina para tratar enfermedades y trastornos. | |
| Gyanewali et al. | Formulation development and in vitro–in vivo assessment of protransfersomal gel of anti-resorptive drug in osteoporosis treatment | |
| Zhang et al. | Adipose fatty acid binding protein promotes saturated fatty acid–induced macrophage cell death through enhancing ceramide production | |
| Singh et al. | Orally active osteoanabolic agent GTDF binds to adiponectin receptors, with a preference for AdipoR1, induces adiponectin-associated signaling, and improves metabolic health in a rodent model of diabetes | |
| JP2011042688A (ja) | 摂食行動の修正 | |
| Sundaresan et al. | Dietary lipids inform the gut and brain about meal arrival via CD36-mediated signal transduction | |
| Manchanda et al. | Spatiotemporal control of GLP-1 receptor activity | |
| Ahn et al. | Undaria pinnatifida extract feeding increases exercise endurance and skeletal muscle mass by promoting oxidative muscle remodeling in mice | |
| Strasser et al. | Nutrition for older athletes: focus on sex-differences | |
| Heppner et al. | Acylation type determines ghrelin's effects on energy homeostasis in rodents | |
| PE20221168A1 (es) | Agonistas del receptor npy2 | |
| Will et al. | Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity | |
| US20220175713A1 (en) | Depside trimeric compounds for skeletal muscle modulation | |
| JP2010180203A (ja) | Gip上昇抑制剤 | |
| Abdel-Malek et al. | Pharmacotherapy for chronic obesity management: a look into the future | |
| Ha et al. | Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus | |
| JP2017509628A5 (cg-RX-API-DMAC7.html) | ||
| US10493042B2 (en) | Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent | |
| JP2019507182A (ja) | 炎症を処置するための化合物および方法 |